Intestinal CYP3A5 genotype and MDR1 expression influence apparent clearance of tacrolimus in adult living-donor liver transplant recipients

被引：0
|
作者：
Fukudo, Masahide
Yoshimura, Atsushi
Yano, Ikuko
Masuda, Satohiro
Uesugi, Miwa
Hosohata, Keiko
Katsura, Toshiya
Takada, Yasutsugu
Uemoto, Shinji
Inui, Ken-ichi
机构：
[1] Kyoto Univ Hosp, Dept Pharm, Kyoto 606, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Transplantat & Immunol, Kyoto, Japan
来源：
THERAPEUTIC DRUG MONITORING | 2007年 / 29卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
73
引用
收藏
页码：484 / 484
页数：1
相关论文
共 50 条
  • [21] EARLY TACROLIMUS DOSING IN PEDIATRIC LIVER TRANSPLANTATION DEPENDS ON RECIPIENT CYP3A5 AND ABCB1 (or MDR1) GENOTYPES: EXPERIENCE IN LIVING DONOR RECIPIENTS
    Guy-Viterbo, Vanessa
    Panain, Nadtha
    Janssen, Magdalena
    Elens, Laure
    Reding, Raymond
    Haufroid, Vincent
    Wallemacq, Pierre
    PEDIATRIC TRANSPLANTATION, 2013, 17 : 43 - 43
  • [22] TACROLIMUS FIRST DOSE DEPENDS ON RECIPIENT CYP3A5 AND ABCB1 (OR MDR1) GENOTYPES IN PEDIATRIC LIVER TRANSPLANTATION: EXPERIENCE IN LIVING DONOR RECIPIENTS
    Guy-Viterbo, Vanessa
    Panain, Nadtha
    Janssen, Magdalena
    Elens, Laure
    Reding, Raymond
    Haufroid, Vincent
    Wallemacq, Pierre
    TRANSPLANT INTERNATIONAL, 2013, 26 : 199 - 199
  • [23] Early Tacrolimus Dosing in Pediatric Liver Transplantation Depends on Recipient CYP3A5 and ABCB1 (or MDR1) Genotypes: Experience in Living Donor Recipients
    Guy-Viterbo, V.
    Panain, N.
    Janssen, M.
    Elens, L.
    Reding, R.
    Haufroid, V
    Wallemacq, P.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 707 - 707
  • [24] CYP3A5 and MDR1 genetic polymorphisms and correlation with tacrolimus pharmacokenetics in Chinese liver transplant patients
    Li, Dan
    Zhu, Ji-Ye
    Gao, Jie
    Lou, Ya-Qing
    Zhang, Guo-Liang
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 228 - 229
  • [25] CYP3A5 Genotype Had no Impact on Intrapatient Variability of Tacrolimus Clearance in Renal Transplant Recipients
    Spierings, N.
    Holt, D. W.
    MacPhee, Iain A. M.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (03) : 328 - 331
  • [26] Impact of MDR1 and CYP3A5 Genetic Polymorphisms on Tacrolimus Dosage Requirements and Acute Rejection in Caucasian Liver Transplant Recipients.
    Brunet Serra, Merce
    Gomez Bravo, Miguel Angel
    Salcedo, Magdalena
    Fondevilla, Constantino
    Suarez, Francisco
    Castellote, Jose
    Rufian, Sebastian
    Pons, Jose A.
    Bilbao, Itxarone
    LIVER TRANSPLANTATION, 2011, 17 (06) : S150 - S150
  • [27] RECIPIENTS' MDR1 AND CYP3A5 GENOTYPES BOTH IMPACT TACROLIMUS DOSE REQUIREMENTS AFTER LIVER TRANSPLANTATION
    Maschmeier, Miriam
    Cicinnati, Vito R.
    Iacob, Speranta
    Radtke, Arnold
    Schomacher, Tina
    Kabar, Iyad
    Huesing, Anna
    Wilms, Christian
    Schmidt, Hartmut
    Beckebaum, Susanne
    TRANSPLANT INTERNATIONAL, 2013, 26 : 202 - 202
  • [28] Influence of donor CYP3A5 gene polymorphism on tacrolimus dose requirement in pediatric liver transplant recipients
    Ayme, E.
    Debray, D.
    Durand, P.
    Fabre, M.
    Furlan, V.
    Bouligand, J.
    Kolaci, M.
    Verstuyft, C.
    Becquemont, L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 75 - 75
  • [29] Influence of the Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients
    Ferraresso, Mariano
    Tirelli, Amedea
    Ghio, Luciana
    Grillo, Paolo
    Martina, Valentina
    Torresani, Erminio
    Edefonti, Alberto
    PEDIATRIC TRANSPLANTATION, 2007, 11 (03) : 296 - 300
  • [30] Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CMC19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients
    Miura, Masatomo
    Inoue, Kazuyuki
    Kagaya, Hideaki
    Satoh, Shigeru
    Tada, Hitoshi
    Sagae, Yoshinori
    Habuchi, Tomonori
    Suzuki, Toshio
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2007, 28 (04) : 167 - 175
12345